Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ong

Showing results (41-50 of 117) with videos related to

Pageof 12
Sort By:
NMR in Biomedicine|November 13, 2024
Orientation-independent quantification of macromolecular proton fraction in tissues with suppression of residual dipolar couplingZijian Gao, Ziqiang Yu, Ziqin Zhou, et al.
Current Oncology (Toronto, Ont.)|July 25, 2022
Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for OncologistsIrena Druce, Karine Tawagi, Julie L V Shaw, et al.
Journal of General Internal Medicine|September 25, 2025
A Novel Intervention for Medicaid Beneficiaries with Complex NeedsLuke Mueller, Neil Batlivala, Jonathan Palisoc, et al.
Journal of the American Academy of Dermatology|March 14, 2024
Spironolactone treatment for dermatologic indications is not associated with hypotension in a single-center retrospective studyRachel C Hill, Yu Wang, Bilal Shaikh, et al.
Cancer Chemotherapy and Pharmacology|April 3, 2020
Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancerIgal Kushnir, Ranjeeta Mallick, Michael Ong, et al.
Medical Oncology (Northwood, London, England)|January 23, 2019
The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicityIgal Kushnir, Kim Koczka, Michael Ong, et al.
Nature Reviews. Clinical Oncology|October 17, 2013
Appraising iniparib, the PARP inhibitor that never was--what must we learn?Joaquin Mateo, Michael Ong, David S P Tan, et al.
Journal of Public Health Management and Practice : JPHMP|May 29, 2012
The public health disaster trust scale: validation of a brief measureDavid P Eisenman, Malcolm V Williams, Deborah Glik, et al.
Cancers|April 30, 2021
Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic ReviewKerianne Boulva, Sameer Apte, Ashley Yu, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 9, 2022
Assessment of the epidemiological trends for prostate cancer using administrative data in OntarioFred Saad, Bimal Bhindi, Krista Noonan, et al.
Pageof 12

Showing results (41-50 of 117) with videos related to

Sort By:
Pageof 12
NMR in Biomedicine|November 13, 2024
Orientation-independent quantification of macromolecular proton fraction in tissues with suppression of residual dipolar couplingZijian Gao, Ziqiang Yu, Ziqin Zhou, et al.
Current Oncology (Toronto, Ont.)|July 25, 2022
Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for OncologistsIrena Druce, Karine Tawagi, Julie L V Shaw, et al.
Journal of General Internal Medicine|September 25, 2025
A Novel Intervention for Medicaid Beneficiaries with Complex NeedsLuke Mueller, Neil Batlivala, Jonathan Palisoc, et al.
Journal of the American Academy of Dermatology|March 14, 2024
Spironolactone treatment for dermatologic indications is not associated with hypotension in a single-center retrospective studyRachel C Hill, Yu Wang, Bilal Shaikh, et al.
Cancer Chemotherapy and Pharmacology|April 3, 2020
Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancerIgal Kushnir, Ranjeeta Mallick, Michael Ong, et al.
Medical Oncology (Northwood, London, England)|January 23, 2019
The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicityIgal Kushnir, Kim Koczka, Michael Ong, et al.
Nature Reviews. Clinical Oncology|October 17, 2013
Appraising iniparib, the PARP inhibitor that never was--what must we learn?Joaquin Mateo, Michael Ong, David S P Tan, et al.
Journal of Public Health Management and Practice : JPHMP|May 29, 2012
The public health disaster trust scale: validation of a brief measureDavid P Eisenman, Malcolm V Williams, Deborah Glik, et al.
Cancers|April 30, 2021
Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic ReviewKerianne Boulva, Sameer Apte, Ashley Yu, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 9, 2022
Assessment of the epidemiological trends for prostate cancer using administrative data in OntarioFred Saad, Bimal Bhindi, Krista Noonan, et al.
Pageof 12